نتایج جستجو برای: tositumomab

تعداد نتایج: 347  

Journal: :Hematology/oncology clinics of North America 2016
Julia Carnevale James L Rubenstein

Primary central nervous system (CNS) lymphoma is a challenging subtypes of aggressive non-Hodgkin lymphoma. Emerging clinical data suggest that optimized outcomes are achieved with dose-intensive CNS-penetrant chemotherapy and avoiding whole brain radiotherapy. Anti-CD20 antibody-based immunotherapy as a component of high-dose methotrexate-based induction programs may contribute to improved out...

Journal: :Blood 2010
Riad Abès Emmanuelle Gélizé Wolf Herman Fridman Jean-Luc Teillaud

The anti-CD20 monoclonal antibody (mAb) rituximab has been used successfully for lymphoma therapy for more than 10 years. Although several direct mechanisms by which anti-CD20 mAbs act have been characterized in vitro, their specific role in clinical efficacy is still debated. Little is known about the possible antitumor immune response that they may induce in patients, despite clinical data su...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004
Wen-Kai Weng Debra Czerwinski John Timmerman Frank J Hsu Ronald Levy

PURPOSE The unique immunoglobulin idiotype (Id) expressed by each B-cell lymphoma is a target for immunotherapy. Vaccination with Id induces humoral and/or cellular anti-Id immune responses. However, the clinical impact of these anti-Id immune responses is unknown. We and others have previously reported that immunoglobulin G Fc receptor (FcgammaR) polymorphisms predict the clinical response of ...

Journal: :P & T : a peer-reviewed journal for formulary management 2010
Efrat Dotan Charu Aggarwal Mitchell R Smith

Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in adults, with B-cell lymphomas accounting for 85% of all NHLs. The most substantial advancement in the treatment of B-cell malignancies, since the advent of combination chemotherapy, has been the addition of the monoclonal anti-CD20 antibody rituximab (Rituxan). Since its initially reported single-agent activity in indol...

2013
M. Fantò S. Salemi F. Socciarelli A. Bartolazzi G. A. Natale I. Casorelli A. Pavan S. Vaglio R. Di Rosa R. D'Amelio

A 30-year-old woman affected by Mixed Connective Tissue Disease with scleroderma spectrum developed a facial eruption, a clinical and histological characteristic of subacute cutaneous lupus erythematosus (SCLE). Speckled anti-nuclear antibodies, high-titer anti-ribonucleoprotein1, anti-Sm, anti-Cardiolipin (aCL) IgG/IgM, and anti-Ro/SSA antibodies were positive. SCLE was resistant to Azathiopri...

2017
Pietro Ravani Alice Bonanni Gian Marco Ghiggeri

INTRODUCTION Oral steroids induce remission in about 90% of children with idiopathic nephrotic syndrome (INS), which is characterised by severe proteinuria and hypoalbuminaemia. Some children become steroid-dependent (SD) and require addition of calcineurin inhibitors (CNI) to maintain remission. Since these oral agents are toxic, alternative interventions are needed for long-term treatment. Th...

Journal: :Annals of the rheumatic diseases 2013
Daniel Aletaha Farideh Alasti Josef S Smolen

BACKGROUND/OBJECTIVE Progression of joint damage is linked to disease activity. This link is dissociated upon treatment with tumour necrosis factor (TNF)- or IL-6-inhibitors plus methotrexate (MTX). It is hitherto unknown if this may also be true for therapies targeting B-cells. We thus evaluated if rituximab (RTX) therapy inhibits joint damage irrespective of its effects on disease activity. ...

2013
Hideaki Kobayashi Yuka Matsunaga Yumiko Uchiyama Kenji Nagura Yasuhiko Komatsu

Cellular activity of BM-ca, a novel humanized anti-CD20 antibody, was quantitatively compared with that of two other anti-CD20 antibodies used for clinical practice, rituximab and ofatumumab. The results of a complement-dependent cytotoxicity (CDC) assay revealed that the strongest antibody was ofatumumab, followed by BM-ca, with rituximab being the weakest. Ofatumumab and BM-ca were effective ...

Journal: :Cell 2011
Elisa Oricchio Gouri Nanjangud Andrew L. Wolfe Jonathan H. Schatz Konstantinos J. Mavrakis Man Jiang Xiaoping Liu Joanne Bruno Adriana Heguy Adam B. Olshen Nicholas D. Socci Julie Teruya-Feldstein Frances Weis-Garcia Wayne Tam Rita Shaknovich Ari Melnick Juha P. Himanen R.S.K. Chaganti Hans-Guido Wendel

Insights into cancer genetics can lead to therapeutic opportunities. By cross-referencing chromosomal changes with an unbiased genetic screen we identify the ephrin receptor A7 (EPHA7) as a tumor suppressor in follicular lymphoma (FL). EPHA7 is a target of 6q deletions and inactivated in 72% of FLs. Knockdown of EPHA7 drives lymphoma development in a murine FL model. In analogy to its physiolog...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید